We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Abliva Ab | LSE:0QDU | London | Ordinary Share | SE0002575340 | ABLIVA ORD SHS |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 2.65 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Med, Dental, Hosp Eq-whsl | 1.48M | -95.51M | -0.0904 | -0.11 | 10.56M |
From May 2019 to May 2024
LUND, Sweden, 25 March 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the English version of the Annual report for 2018 is now available on the company's website www.neurovive.com.
This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 10:00 a.m. CET on 25 March 2019.
About NeuroVive
NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for genetic mitochondrial diseases and one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®). The R&D portfolio also consists of projects for genetic mitochondrial disorders, NASH and cancer. The company advances drugs for rare diseases through clinical development into the market, with or without partners. For projects for common indications the goal is out-licensing in the preclinical phase. A subset of compounds under NeuroVive's NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber's Hereditary Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/neurovive-pharmaceutical/r/neurovive-pharmaceutical-ab-publishes-2018-annual-report,c2771265
The following files are available for download:
https://mb.cision.com/Main/6574/2771265/1012942.pdf | NeuroVive Pharmaceutical AB publishes 2018 Annual report |
For more information please contact:
Catharina Johansson
CFO
IR & Communications
+46 (0)46-275-62-21
ir@neurovive.com
NeuroVive Pharmaceutical AB (publ)
Medicon Village
SE-223 81 Lund, Sweden
Tel: +46 (0)46-275-62-20 (switchboard)
info@neurovive.com, www.neurovive.com
For news subscription, please visit http://www.neurovive.com/press-releases/subscription-page/
Follow us on LinkedIn
Copyright 2019 PR Newswire
1 Year Abliva Ab Chart |
1 Month Abliva Ab Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
